MAIA Biotechnology (NYSEAMERICAN:MAIA) Issues Earnings Results, Beats Estimates By $0.01 EPS

MAIA Biotechnology (NYSEAMERICAN:MAIA) released its earnings results on Monday. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01, FiscalAI reports.

MAIA Biotechnology Trading Up 2.8%

MAIA opened at $1.09 on Tuesday. The stock has a 50-day moving average price of $1.21 and a 200-day moving average price of $1.44. MAIA Biotechnology has a 12-month low of $0.87 and a 12-month high of $3.19. The stock has a market capitalization of $67.30 million, a P/E ratio of -1.76 and a beta of 0.28.

Insider Activity

In other news, Director Ramiro Guerrero bought 78,239 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was bought at an average price of $1.39 per share, for a total transaction of $108,752.21. Following the transaction, the director directly owned 689,081 shares of the company’s stock, valued at $957,822.59. This represents a 12.81% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Vlad Vitoc bought 73,000 shares of the business’s stock in a transaction on Monday, September 14th. The stock was purchased at an average cost of $1.37 per share, with a total value of $100,010.00. Following the purchase, the chief executive officer owned 1,049,121 shares of the company’s stock, valued at $1,437,295.77. This represents a 7.48% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 258,078 shares of company stock worth $352,426 over the last quarter. Corporate insiders own 19.81% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company’s research is centered on treatments designed to address telomere biology, a process that plays an important role in the growth and survival of cancer cells.

MAIA’s lead investigational product is THIO, also known as 6-thio-2′-deoxyguanosine, a telomere-targeting agent intended to selectively affect cancer cells. The company has been evaluating THIO in combination with immune checkpoint inhibitors for patients with advanced or metastatic non-small cell lung cancer, including through its THIO-101 clinical program.

MAIA Biotechnology is headquartered in Chicago and is led by Chief Executive Officer Vlad Vitoc, M.D.